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Conclusion: Distant metastasis remains the major issue in the 
management of LARC. This study demonstrated improvement 
in pCR, as well as the potential to achieve higher survival 
rates, including DFS. Waiting for randomized phase III trials 
long-term follow-up data, OXP should be considered as 
feasible and valid neo-adjuvant treatment option. The low 
rate of severe toxicity and the effective benefit on pCR and 
peri-operative metastasis support this concomitant CHT 
schedule for LARC. 
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Purpose or Objective: To compare the oncologic outcome of 
total mesorectal excision (TME) to local excision (LE) in 
"early" clinical T3 rectal cancer patients who received 
preoperative radiation therapy.  
 
Material and Methods: "Early" clinical T3 patients, who 
underwent preoperative radiation therapy followed by TME or 
LE at Asan Medical Center between January 2007 and 
December 2013 were retrospectively analyzed. "Early" clinical 
T3 was defined as extramural extension ≤ 5mm, 
circumferential resection margin negative and lateral lymph 
node negative in pretreatment magnetic resonance imaging. 
A one-to-one propensity case-matched analysis was used with 
covariates of baseline characteristics. Local recurrence free 
survival (LRFS), disease free survival (DFS), overall survival 
(OS) were compared between the matched two groups. 
 
Results: A total of 425 patients were identified; 366 
underwent TME and 59 underwent LE. The median follow-up 
period was 47 months. After propensity score-matching, we 
obtained 55 matched pairs. There were no significant 
differences in 3-year LRFS (95.8% vs 94.2%, p=0.927), DFS 
(85.7% vs 90.8%, p=0.473), OS (96.2% vs 100%, p=0.987) 
between TME and LE groups.  
 
Conclusion: In "early" clinical T3 rectal cancer, local excision 
could be a feasible alternative to mesorectal excision after 
preoperative chemoradiation.  
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Purpose or Objective: Cervical intraepithelial neoplasia 
(CIN) and anal squamous cell carcinoma (SCC) are both 
causally associated with human papilloma virus infection 
(HPV). Women who have an HPV infection of the cervix are at 
a higher risk of HPV infection of the anal canal with the same 
HPV subtype(1). The incidence of HPV infection and related 
cancers is increasing in developed nations(2). Until the 
impact of widespread HPV vaccination is manifest, 
presentation with multiple HPV related malignancies will 
become a more common clinical scenario. Our objective was 
to identify the proportion of women with anal cancer who 
had a history of CIN or invasive cervical cancer (ICC) and 
discuss the implications for future practice.  
 
Material and Methods: The medical records and 
histopathology of all consecutive women treated definitively 
for anal cancer at our centre between January 2004 and July 
2015 were reviewed. A case was defined as a woman 
reporting a history of CIN or ICC treated with either a cone 
biopsy or hysterectomy. We extracted treatment details of 
both the anal cancer and CIN or ICC, demographic and 
outcome data. Women with a previous abnormal pap smear 
or low grade cervical dysplasia were not included as a case.  
 
Results: Eight cases (25%) were identified; Stage III (63%), I, 
II, IV (each 12.5%). The women were HIV negative, aged 36-
62 years and diagnosed with HPV positive anal SCC 10-40 
years after their initial diagnosis. Of the remaining 24 
women, Nine had no prior history, Four had a previous 
abnormal pap smear, one a partial hysterectomy for unknown 
reason, two a hysterectomy for benign uterine disease and 
eight no recorded gynaecological history. Seven women had 
definitive chemoradiotherapy and one had sequential 
chemotherapy and radiotherapy (Stage IV). All were alive and 
disease free at follow up. 
 
Conclusion: One quarter of women with anal SCC had a 
previous history of CIN or ICC. This may be an underestimate 
as a gynaecological history was missing in 25% of patients. 
There are several implications for practice: the importance 
of specifically elucidating a history of HPV-related disease 
such as warts, CIN or ICC on history; secondly, to have a high 
index of suspicion when these women present with bowel 
symptoms; third, that this represents a high risk group of 
women who may benefit from participation in anal pap 
screening programs similar to that being investigated in high 
risk men. 
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Purpose or Objective: To test the relationship between 
dosimetric data and pathological response in a series of 52 
patients treated with combined pre-operative 
chemoradiation (CRT) for local advanced rectal cancer.. 
 
Material and Methods: We studied 52 consecutive patients 
treated with pre-operative CRT for locally advanced rectal 
cancer (T3-4N0M0 or any TN+M0, G1-3). Total dose 
prescribed was 44 Gy (2 Gy/fx) (Group 1, n = 10) or 45 Gy 
(1.8 Gy/fx) (Group 2, n = 42), delivered using helical 
Tomotherapy (HT). A concomitant Capecitabine-based 
chemotherapy was also delivered. All patients underwent 
surgery 6 to 8 weeks after the end of CRT. Surgery consisted 
of low anterior resection (LAR) or abdominoperineal excision 
(APR), depending on the tumor distance from anal margin. 
For all patients, we calculated pathological response through 
difference between TNM clinical staging and TNM 
pathological staging such as by pathological Dworak tumor 
regression score (TRG). We tested the relationship between 
pathological response and planning target volume (PTV) 
dosimetric criteria in agreement with ICRU 83 and internal 
guidelines. Selected parameters were: Dmax, Dmin, 
Dmean,D98,D95, D2, V95,V100 ,V107, V110 and target 
volume (cc). Non-parametric statistical analysis (Wilcoxon, U-
Mann-Whitney, Kruskal-Wallis tests) was performed using 
SPSS.21 software (significant level p < 0.05). Planning 
dosimetric data were extracted from patient archives using 
VODCA 5.4.0. 
 
Results: Results: A significant reduction in TNM staging was 
observed post-treatment (p < 0.001 and p < 0.010 for T & N, 
respectively). Furthermore, 3 patients presented a total 
remission (5.8%) and 30 remained stable (57.7%). For Group 
1, average values and standard deviation of Dmean, Dmin and 
Dmax (Gy) were 44.5 ± 0.4, 30.4 ± 3.6, and 47.2 ± 0.3, while 
for Group 2 were 45.1 ± 0.3, 33.1 ± 3.5, and 48.1 ± 0.6. Dose 
